Raymond James raised the firm’s price target on BridgeBio (BBIO) to $69 from $59 and keeps an Outperform rating on the shares after the company announced positive interim topline data from the ongoing Phase 3 FORTITUDE study of BBP-418 in LGMD2I/R9. Expectations for BBP-418 were muted, and these results support a bull case outlook and provide visibility on a more rapid path to market, the analyst tells investors in a research note. The firm added that moving the launch forward and de-risking approval result in its increased price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Midday Fly By: Novartis to buy Avidity, Keurig Dr Pepper beats expectations
- BridgeBio reports results from FORTIFY Phase 3 study of BBP-418
- BridgeBio management to meet with Piper Sandler
- Positive Outlook on BridgeBio Pharma Driven by Promising Pipeline and Strategic Initiatives
- BridgeBio presented data from ATTRibute-CM study on acoramidis